Conference Proceedings
Observations from the OMERACT Drug Safety Summit, May 2008
LS Simon, CV Strand, M Boers, PM Brooks, D Henry, PS Tugwell
Journal of Rheumatology | J RHEUMATOL PUBL CO | Published : 2009
Abstract
Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology Copyright © 2009. All rights reserved.